The Elements of an Effective Solid-Dosage Metal Detection Program - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Elements of an Effective Solid-Dosage Metal Detection Program
The author discusses new detection-system technologies that can improve performance and provides key criteria to consider when selecting or upgrading a system for pharmaceutical use.


Pharmaceutical Technology
Volume 34, pp. S22-S25

Selecting a detection system


Table I: Typical detectable metal diameter versus metal detector's aperture size.
There are many criteria to consider when evaluating metal-detection systems for tablet and capsule processing. Perhaps the most important is the system's sensitivity (i.e., how small a metal fragment can be detected [the typical range for pharmaceutical applications is less than 0.5 mm]) and how immune the system is to outside influences such as vibration and electromagnetic noise, which can cause false rejects (see Table I). When selecting the size of the system's aperture, one should consider performance as well as throughput and size to avoid product jams during production.

Sensitivity. One subtle, but important, factor to consider when evaluating different systems is what, if any, effect a product might have on the metal detector. Most tablets and capsules look like "dry" products to the metal detector, but it is possible that they may trigger a false reject if they contain significant concentrations of metal elements such as iron. If a false reject continually occurs, the detector's operating threshold can be desensitized, but this change may reduce the system's performance. Before selecting a system, therefore, it is important to test the complete system on all of the pharmaceutical products that may be used to determine how the system will perform in a production setting.


Table II: Key criteria for selecting a pharmaceutical metal detection system.
Once it is determined that a system can detect the smallest fragments of metal possible with no chance of false rejection, there are other aspects of the system to consider to ensure that it can be successfully used in a particular production process. Table II provides a list of key questions to ask when evaluating a system.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here